跳至主要内容
临床试验/NCT02797769
NCT02797769已完成不适用

Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases

Hoffmann-La Roche0 个研究点目标入组 48,950 人开始时间: 2016年6月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
48,950
主要终点
Time to First Event of Myocardial Infarction (MI) or Stroke with Tocilizumab Versus Tumor Necrosis Factor Inhibitor (TNFi) Therapies

研究概览

简要总结

This retrospective cohort study will analyze data from multiple large U.S. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying anti-rheumatic drugs (DMARDs) in real world patients with RA. Using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 1 inpatient or 2 outpatient diagnoses of RA
  • Continuous medical/pharmacy coverage and full claims data available
  • At least 6 months of insurance plan enrollment prior to index date

排除标准

  • Nursing home residents
  • Human immunodeficiency virus (HIV)
  • Malignancy
  • Receipt of chemotherapy
  • End-stage renal disease, dialysis, or transplant
  • Use of rituximab
  • Recent cardiovascular event (includes MI, stroke, ACS, or HF) within 90 days prior to index date

研究组 & 干预措施

Non-TNFi Biologics

Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.

干预措施: Other Biologics (Drug)

TNFi Biologics

Real world patients with RA with a dispensing history for TNFi biologics will be included.

干预措施: Other Biologics (Drug)

Tocilizumab

Real world patients with RA with a dispensing history for tocilizumab will be included.

干预措施: Tocilizumab (Drug)

结局指标

主要结局

Time to First Event of Myocardial Infarction (MI) or Stroke with Tocilizumab Versus Tumor Necrosis Factor Inhibitor (TNFi) Therapies

时间窗: Up to approximately 1 year from index date

次要结局

  • Time to First Event of MI or Stroke with Tocilizumab Versus Non-TNFi Therapies(Up to approximately 1 year from index date)
  • Time to Hospitalization for Coronary Revascularization Procedure(Up to approximately 1 year from index date)
  • Time to Hospitalization for Acute Coronary Syndrome (ACS)(Up to approximately 1 year from index date)
  • Time to First Event of MI, Stroke, Coronary Revascularization Procedure, or ACS(Up to approximately 1 year from index date)
  • Time to Heart Failure (HF) Requiring Hospitalization(Up to approximately 1 year from index date)
  • Time to All-Cause Death(Up to approximately 1 year from index date)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验